Late May brought a sweeping HHS Lyme initiative that pairs new tick-control funding with a public-private partnership directing patients to providers affiliated with the International Lyme and Associated Diseases Society.
That tie-up is controversial because ILADS endorses 'chronic Lyme,' a diagnosis mainstream medicine largely rejects; standard Lyme usually clears with 2- to 4-week antibiotics, while lingering symptoms affect about 10% after treatment.
Trials have not shown months-long antibiotics improve post-treatment Lyme symptoms, and critics say promoting Lyme-literate care risks steering patients toward unproven or dangerous interventions.
CDC-linked researchers in 2017 documented at least five serious complications tied to chronic Lyme treatment, including one septic-shock death, while some Lyme-focused clinicians have faced state sanctions.
Lyme still infects roughly 500,000 Americans a year, and specialists welcomed more attention and research, but urged HHS to prioritize evidence-based care and noted the plan gives little emphasis to vaccines.